BiomX Inc. (PHGE) CEO Jonathan Solomon on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
BiomX Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 05/11/22
BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis PatientsBusiness Wire • 05/06/22
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022Business Wire • 05/05/22
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/30/22
BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateBusiness Wire • 03/30/22
BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022Business Wire • 03/23/22
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis FoundationBusiness Wire • 01/04/22
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/15/21
BiomX Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/15/21
Down 28.1% in 4 Weeks, Here's Why BiomX Inc. (PHGE) Looks Ripe for a TurnaroundZacks Investment Research • 10/25/21
BiomX Enters Agreement Granting Maruho Co. A right Of First Offer To License BiomX's Atopic Dermatitis Product Candidate BX005; Maruho Will Also Enter Binding Agreement For $3M Equity Investment In BiomXBenzinga • 10/13/21
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005GlobeNewsWire • 10/13/21
BiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/16/21
BiomX Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/16/21
BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021GlobeNewsWire • 08/12/21